Journal
JOURNAL OF ALZHEIMERS DISEASE
Volume 60, Issue 1, Pages 283-292Publisher
IOS PRESS
DOI: 10.3233/JAD-170129
Keywords
Alzheimer's disease; amyloid beta-peptides; cerebrospinal fluid proteins; positron emission tomography; tau proteins
Categories
Funding
- MRC
- NIHR as part of Dementias Platform UK
- Medical Research Council [MR/L023784/1, MR/M024962/1, MC_UU_00005/12, MR/N029941/1, MR/L023784/2, MC_EX_MR/N50192X/1, MC_U105597119] Funding Source: researchfish
- National Institute for Health Research [CL-2015-13-007] Funding Source: researchfish
- Parkinson's UK [J-1403] Funding Source: researchfish
- Wellcome Trust [103838/Z/14/Z] Funding Source: researchfish
- MRC [MR/L023784/2, MR/L023784/1, MR/M024962/1, MR/N029941/1, MC_U105597119, MC_EX_MR/N50192X/1, MC_UU_00005/12] Funding Source: UKRI
Ask authors/readers for more resources
Background: Combining PET amyloid-beta (A beta) and tau imaging may be critical for tracking disease progression in Alzheimer's disease (AD). Objective: We sought to characterize the relationship between A beta and tau ligands as well as with other measures of pathology. Methods: We conducted a multi-center observational study in early AD (MMSE > 20) participants aged 50 to 85 y. The schedule included cognitive assessments (ADAS-Cog) and CSF measurement of A beta and tau at baseline and 6 months; PET-CT imaging with A beta ([(18F)] AV45) and tau ([(18F)] AV1451) ligands at baseline. Results: 22 participants took part in the study with 20 completing its 6-month duration and 12 having both tau and amyloid PET. The PET biomarker analysis revealed a strong negative correlation between age and tau in multiple regions. Entorhinal cortex tau and age interacted significantly in terms of cognitive change over 6 months which may have been to older participants deteriorating faster despite lower levels of cortical tau. Cortical A beta associated with entorhinal cortex tau while CSF tau/A beta ratio correlated strongly with cortical tau but not A beta. Conclusion: The negative relationship between age and cortical tau whereby younger patients with mild AD had relatively greater tau burden is potentially important. It suggests that younger-age onset AD may be primarily driven by tau pathology while AD developing later may depend on a multitude of pathological mechanisms. These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker-the CSF total tau/A beta ratio.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available